ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis
The ESM1-ANGPTL4-FASN-trioleate axis orchestrates metabolic reprogramming and endothelial activation, representing a promising therapeutic target. Future studies should explore combination therapies targeting this axis and overcoming bevacizumab resistance in HCC.
Authors
- Caixi Tang (ORCID: https://orcid.org/0009-0004-2006-4471)
- Zhijian Zhao (ORCID: https://orcid.org/0000-0001-5988-7599)
- Zhengwu Jiang
- Jian Wan
- Yukun Li
- Dong Wang
- Xun Chen
Institutions
- Central South University (CN)
- Dalian Medical University (CN)
- Dalian Municipal Central Hospital (CN)
- Zhuzhou Central Hospital (CN)
Publication Details
- Journal
- Neoplasia
- Published
- 2026-03-20
- DOI
- https://doi.org/10.1016/j.neo.2026.101298
- Primary Topic
- Inflammation biomarkers and pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00